Julia Rossié

Dr. Julia Rossié

Baker McKenzie Rechtsanwaltsgesellschaft mbH von Rechtsanwälten und Steuerberatern


Dr. Julia Rossié is a senior associate in the Corporate/M&A Practice Group in Munich who advises domestic and international clients on a wide range of corporate matters, focusing on mergers and acquisitions (M&A), private equity, growth capital, and venture capital transactions. She has a particular focus on the healthcare and life sciences industry.

Practice Focus

Julia advises national and international financial investors, private equity funds, strategic clients, and family offices on a wide range of corporate transactions. Julia also has a deep understanding of the legal, intellectual property and regulatory issues involved in these transactions.

Representative Legal Matters

  • Advised Evonik Industries AG on its virtually held annual general meeting.
  • Advised Seamless Therapeutics on USD 12.5 million Financing and In-Licensing from TU Dresden.
  • Advised Ariceum Therapeutics on a Serie A Financing - co-led by EQT Life Sciences (formerly LSP) and HealthCap - and on an Asset Acquisition from Ipsen Pharma.
  • Advised CatalYm GmbH, an innovative biotech company developing novel cancer immunotherapies, on the closing of its EUR 50 million Series B equity financing. 
  • Advised AURELIUS Equity Opportunities SE & Co. KGaA on the sale of its subsidiary GHOTEL hotel & living to the Cologne-based Art-Invest Real Estate Group.
  • Advised Parkmobile Group Holding B.V., a provider of cashless parking payment solutions and related services, on its acquisition of all shares in Berlin based Parkling GmbH, a provider of on-street mobility services.
  • Advised the German biotech company MODAG on the in-licensing of an innovative substance portfolio (SERY 433) from Max Planck Innovation GmbH to combat neurodegenerative diseases and on the closing of a EUR 12 million Series A financing round, led by the Massa Investment AG, Switzerland.
  • Advised Hitachi Chemical Company, Ltd., a leading manufacturer of functional materials and advanced components with a strong portfolio in the life sciences industry, on the takeover of German apceth Biopharma, a contract development and manufacturing organization for complex cell-based regenerative gene therapy products.


  • Germany (2018)


  • Higher Regional Court of Hamburg (Assessor Exam) (2018)
  • University of Munich (Legal Clerk Exam) (2013)
  • Qingdao University (2011)
  • University of Salamanca (2011)


  • English
  • German
  • Spanish